Last reviewed · How we verify
NCT05990452
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
Phase 1, PHASE2 trial testing 9MW2921 in Advanced Solid Tumor in 261 participants. Participants enrolled and being followed up; not accepting new ones.
1 September 2026
Quick facts
| Lead sponsor | Mabwell (Shanghai) Bioscience Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 261 |
| Start date | 28 August 2023 |
| Primary completion | 1 September 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- 9MW2921 — full drug profile →
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, Phase I-II, first-in-human (FIH) study of 9MW2921 in patients with locally advanced or metastatic solid tumors refractory to all standard therapies. The objective of this study is to evaluate the safety, tolerability, PK, immunogenicity and Preliminary Antitumor Activity of 9MW2921.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Trop2-targeted therapies in solid tumors: advances and future directions.
Liu X, Ma L, Li J, Sun L, et al · · 2024 · cited 54× · PMID 38948057 · DOI 10.7150/thno.98178 -
Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.
Chow R, Zhang D, Kannout S, Ma A, et al · · 2026 · PMID 42068413 · DOI 10.1007/s00520-026-10674-2
Verify or expand the search:
- PubMed search for NCT05990452
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Other Mabwell (Shanghai) Bioscience Co., Ltd. trials
Trials by the same sponsor.
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07314723 — 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer · Phase 2 · recruiting
- NCT06926998 — 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT06804590 — A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis · Phase 3 · recruiting
- NCT06692166 — A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Ca · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05990452 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mabwell (Shanghai) Bioscience Co., Ltd.
- Last refreshed: 21 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05990452.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing